OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety

Background: Pheochromocytoma/Paraganglioma (PPGL) are rare neuroendocrine tumors with a 5-yr survival rate as low as 12%. There is a high unmet medical need for effective treatment options for patients with advanced disease. AZEDRA(®), a high-specific-activity iodine-131 meta-iodobenzylguanidine (HS...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Endocr Soc
Autori principali: Jimenez, Camilo, Chin, Bennett B, Noto, Richard B, Dillon, Joseph Stephen, Solnes, Lilja B, DiPippo, Vincent A, Stambler, Nancy, Wong, Vivien, Pryma, Daniel A
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Adrenal
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7208024/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1241
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi